IP Library Granted Patent US 8,598,120
Granted Patent B2
US 8,598,120 · App. 13/364,250 · Granted Dec 3, 2013

Methods for treatment using amylin family peptides

Inventors: Christopher J. Soares (La Jolla, CA); Michael R. Hanley (Corte Madera, CA); Diana Y. Lewis (San Diego, CA); David G. Parkes (Del Mar, CA); Carolyn M. Jodka (Encinitas, CA); Kathryn S. Prickett (Foster City, CA); Soumitra S. Ghosh (San Diego, CA); Christine M. Mack (San Diego, CA); Qing Lin (Getzville, NY)
Assignees: Amylin Pharmaceuticals, LLC; AstraZeneca Pharmaceuticals LP
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,598,120
App. No.
13/364,250
Granted
Dec 3, 2013
Kind
B2
Abstract

The present invention relates to novel compounds having a function of a peptide in the amylin family, related nucleic acids, expression constructs, host cells, and processes production of the compounds. The compounds of the invention include one or more amino acid sequence modifications. In addition, methods and compositions are disclosed to treat and prevent metabolic disorders such as obesity, diabetes, and increased cardiovascular risk.

Claims (8)

1. A method of treating eating disorders, insulin-resistance, obesity, abnormal postprandial hyperglycemia, diabetes of any kind, including Type I, Type II, and gestational diabetes, Metabolic Syndrome, Dumping Syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, pulmonary hypertension, cholecystitis, or osteoarthritis comprising administering to a subject in need thereof an effective amount of a peptide having at least 92% sequence identity to the amino acid sequence of SEQ ID NO:137.

2. The method of claim 1 , wherein the peptide having at least 92% sequence identity comprises the amino acid sequence of SEQ ID NO:55, 67, 70, 73, 82, 83, 84, 89, 94, 100, 103, 106, 107, 111, 112, 125, 133, or 137.

3. The method of claim 1 , wherein the peptide having at least 92% sequence identity comprises the amino acid sequence of SEQ ID NO:137.

4. The method of claim 1 , wherein the peptide is linked to a polyethylene glycol polymer, a polyamino acid, or a fatty acid.

5. A method of treating eating disorders, insulin-resistance, obesity, abnormal postprandial hyperglycemia, diabetes of any kind, including Type I, Type II, and gestational diabetes, Metabolic Syndrome, Dumping Syndrome, hypertension, dyslipidemia, cardiovascular disease, hyperlipidemia, sleep apnea, pulmonary hypertension, cholecystitis, or osteoarthritis comprising administering to a subject in need thereof an effective amount of a peptide having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:137.

6. The method of claim 5 , wherein the peptide having at least 95% sequence identity comprises the amino acid sequence of SEQ ID NO:40, 42, 43, 46, 47, 48, 54, 64, 65, 68, 69, 74, 78, 79, 80, 81, 85, 90, 91, 92, 93, 95, 96, 97, 98, 99, 101, 102, 109, 118, 119, 121, 130, or 137.

7. The method of claim 5 , wherein the peptide having at least 95% sequence identity comprises the amino acid sequence of SEQ ID NO:137.

8. The method of claim 5 , wherein the peptide is linked to a polyethylene glycol polymer, a polyamino acid, or a fatty acid.

Assignments (3)
AMYLIN PHARMACEUTICALS, LLC ASSIGNS AN EQUAL AND UNDIVIDED ONE-HALF OF ITS ENTIRE RIGHT, TITLE AND INTEREST TO ASTRAZENECA PHARMACEUTICALS LP Recorded Mar 22, 2013
From: AMYLIN PHARMACEUTICALS, LLC
To: ASTRAZENECA PHARMACEUTICALS LP
Reel/Frame 030064/0611 →
CHANGE OF NAME Recorded Mar 22, 2013
From: AMYLIN PHARMACEUTICALS, INC.
To: AMYLIN PHARMACEUTICALS, LLC
Reel/Frame 030070/0542 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2012
From: SOARES, CHRISTOPHER J.; HANLEY, MICHAEL R.; PARKES, DAVID GEOFFREY; JODKA, CAROLYN MARIE; GHOSH, SOUMITRA S.; MACK, CHRISTINE M.; LIN, QING; LEWIS, DIANA Y.; PRICKETT, KATHRYN S.
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 027642/0576 →
Continuity (4)
Division 10589054
Provisional Application 60543275 · Feb 11, 2004
Provisional Application 60550447 · Mar 3, 2004
Related Publication 20120196796A1 · Aug 2, 2012